메뉴 건너뛰기




Volumn 22, Issue 28, 2016, Pages 6345-6361

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Author keywords

BRAF; Epidermal growth factor receptor; KRAS; MET; Metastatic colorectal cancer; Monoclonal antibodies; Mutation; NRAS; PIK3CA; Resistance

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN P21;

EID: 84979628367     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i28.6345     Document Type: Review
Times cited : (93)

References (135)
  • 3
    • 84911474269 scopus 로고    scopus 로고
    • Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • PMID: 25190710
    • Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii1-iii9 [PMID: 25190710 DOI: 10.1093/annonc/mdu260]
    • (2014) Ann Oncol , vol.25 , pp. iii1-iii9
    • Van Cutsem, E.1    Cervantes, A.2    Nordlinger, B.3    Arnold, D.4
  • 5
    • 0035256698 scopus 로고    scopus 로고
    • Untangling the ERBB signalling network
    • PMID: 11252954
    • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137 [PMID: 11252954 DOI: 10.1038/35052073]
    • (2001) Nat Rev Mol Cell Biol , vol.2 , pp. 127-137
    • Yarden, Y.1    Sliwkowski, M.X.2
  • 6
    • 18344390418 scopus 로고    scopus 로고
    • ERBB receptors and cancer: The complexity of targeted inhibitors
    • PMID: 15864276
    • Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354 [PMID: 15864276 DOI: 10.1038/nrc1609]
    • (2005) Nat Rev Cancer , vol.5 , pp. 341-354
    • Hynes, N.E.1    Lane, H.A.2
  • 7
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • PMID: 18337605
    • Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174 [PMID: 18337605 DOI: 10.1056/NEJMra0707704]
    • (2008) N Engl J Med , vol.358 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 8
    • 69949127786 scopus 로고    scopus 로고
    • Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
    • PMID: 19737224
    • Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 1-9 [PMID: 19737224 DOI: 10.1111/j.1365-2249.2009.03992.x]
    • (2009) Clin Exp Immunol , vol.158 , pp. 1-9
    • Martinelli, E.1    De Palma, R.2    Orditura, M.3    De Vita, F.4    Ciardiello, F.5
  • 9
    • 84899981129 scopus 로고    scopus 로고
    • Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study
    • PMID: 24739896
    • Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R. Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15: 569-579 [PMID: 24739896 DOI: 10.1016/S1470-2045(14)70118-4]
    • (2014) Lancet Oncol , vol.15 , pp. 569-579
    • Price, T.J.1    Peeters, M.2    Kim, T.W.3    Li, J.4    Cascinu, S.5    Ruff, P.6    Suresh, A.S.7    Thomas, A.8    Tjulandin, S.9    Zhang, K.10    Murugappan, S.11    Sidhu, R.12
  • 11
    • 34147103678 scopus 로고    scopus 로고
    • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    • PMID: 17470858
    • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]
    • (2007) J Clin Oncol , vol.25 , pp. 1658-1664
    • Van Cutsem, E.1    Peeters, M.2    Siena, S.3    Humblet, Y.4    Hendlisz, A.5    Neyns, B.6    Canon, J.L.7    Van Laethem, J.L.8    Maurel, J.9    Richardson, G.10    Wolf, M.11    Amado, R.G.12
  • 12
    • 84908431348 scopus 로고    scopus 로고
    • Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
    • PMID: 25293556
    • Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4: 1269-1280 [PMID: 25293556 DOI: 10.1158/2159-8290. CD-14-0462]
    • (2014) Cancer Discov , vol.4 , pp. 1269-1280
    • Misale, S.1    Nicolantonio, F.D.I.2    Sartore-Bianchi, A.3    Siena, S.4    Bardelli, A.5
  • 13
    • 84914112343 scopus 로고    scopus 로고
    • Tumour heterogeneity and the evolution of polyclonal drug resistance
    • PMID: 25087573
    • Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014; 8: 1095-1111 [PMID: 25087573 DOI: 10.1016/j.molonc.2014.06.005]
    • (2014) Mol Oncol , vol.8 , pp. 1095-1111
    • Burrell, R.A.1    Swanton, C.2
  • 14
    • 84884365015 scopus 로고    scopus 로고
    • The causes and consequences of genetic heterogeneity in cancer evolution
    • PMID: 24048066
    • Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345 [PMID: 24048066 DOI: 10.1038/nature12625]
    • (2013) Nature , vol.501 , pp. 338-345
    • Burrell, R.A.1    McGranahan, N.2    Bartek, J.3    Swanton, C.4
  • 16
    • 84929141867 scopus 로고    scopus 로고
    • Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials
    • PMID: 25115304
    • Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21 [PMID: 25115304 DOI: 10.1093/annonc/mdu378]
    • (2015) Ann Oncol , vol.26 , pp. 13-21
    • Sorich, M.J.1    Wiese, M.D.2    Rowland, A.3    Kichenadasse, G.4    McKinnon, R.A.5    Karapetis, C.S.6
  • 23
    • 0024376173 scopus 로고
    • Ras oncogenes in human cancer: A review
    • PMID: 2547513
    • Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689 [PMID: 2547513]
    • (1989) Cancer Res , vol.49 , pp. 4682-4689
    • Bos, J.L.1
  • 28
    • 84979537937 scopus 로고    scopus 로고
    • European Medicines Agency. Committee for Medicinal Products for Human Use. May 2008 Plenary Meeting Monthly Report
    • European Medicines Agency. Committee for Medicinal Products for Human Use. May 2008 Plenary Meeting Monthly Report. Available from: URL: http://www.emea.europa.eu/pdfs/human/press/pr/27923508en.pdf
  • 33
    • 84905870196 scopus 로고    scopus 로고
    • PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
    • PMID: 24687833
    • Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247 [PMID: 24687833 DOI: 10.1200/JCO.2013.53.2473]
    • (2014) J Clin Oncol , vol.32 , pp. 2240-2247
    • Schwartzberg, L.S.1    Rivera, F.2    Karthaus, M.3    Fasola, G.4    Canon, J.L.5    Hecht, J.R.6    Yu, H.7    Oliner, K.S.8    Go, W.Y.9
  • 38
    • 84979540105 scopus 로고    scopus 로고
    • European Medicines Agency. Committee for Medicinal Products for Human Use. Available from
    • European Medicines Agency. Committee for Medicinal Products for Human Use. Available from: URL: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000558/WC500160158.pdf
  • 39
    • 84979540107 scopus 로고    scopus 로고
    • European Medicines Agency. Committee for Medicinal Products for Human Use
    • European Medicines Agency. Committee for Medicinal Products for Human Use. Available from: URL http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000741/WC500148667.pdf
  • 45
    • 84867117207 scopus 로고    scopus 로고
    • Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab
    • PMID: 22734028
    • Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577 [PMID: 22734028 DOI: 10.1200/JCO.2012.42.2592]
    • (2012) J Clin Oncol , vol.30 , pp. 3570-3577
    • Tejpar, S.1    Celik, I.2    Schlichting, M.3    Sartorius, U.4    Bokemeyer, C.5    Van Cutsem, E.6
  • 46
    • 84955282009 scopus 로고    scopus 로고
    • Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
    • PMID: 26812186
    • Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer 2016; 55: 122-130 [PMID: 26812186 DOI: 10.1016/j.ejca.2015.11.025]
    • (2016) Eur J Cancer , vol.55 , pp. 122-130
    • Rowland, A.1    Dias, M.M.2    Wiese, M.D.3    Kichenadasse, G.4    McKinnon, R.A.5    Karapetis, C.S.6    Sorich, M.J.7
  • 47
    • 84949991071 scopus 로고    scopus 로고
    • Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
    • PMID: 26371285
    • Schirripa M, Loupakis F, Lonardi S, Cremolini C, Bergamo F, Zagonel V, Falcone A. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol 2015; 26: 2503 [PMID: 26371285 DOI: 10.1093/annonc/mdv385]
    • (2015) Ann Oncol , vol.26 , pp. 2503
    • Schirripa, M.1    Loupakis, F.2    Lonardi, S.3    Cremolini, C.4    Bergamo, F.5    Zagonel, V.6    Falcone, A.7
  • 51
    • 23844517889 scopus 로고    scopus 로고
    • A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study
    • PMID: 16133800
    • Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 2005; 23: 485-487 [PMID: 16133800 DOI: 10.1007/s10637-005-2908-y]
    • (2005) Invest New Drugs , vol.23 , pp. 485-487
    • Macdonald, J.S.1    McCoy, S.2    Whitehead, R.P.3    Iqbal, S.4    Wade, J.L.5    Giguere, J.K.6    Abbruzzese, J.L.7
  • 54
    • 84888639050 scopus 로고    scopus 로고
    • K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
    • PMID: 24256730
    • Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548-551 [PMID: 24256730 DOI: 10.1038/nature12796]
    • (2013) Nature , vol.503 , pp. 548-551
    • Ostrem, J.M.1    Peters, U.2    Sos, M.L.3    Wells, J.A.4    Shokat, K.M.5
  • 56
    • 84921415334 scopus 로고    scopus 로고
    • Recent therapeutic advances in the treatment of colorectal cancer
    • PMID: 25341011
    • Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med 2015; 66: 83-95 [PMID: 25341011 DOI: 10.1146/annurev-med-051513-102539]
    • (2015) Annu Rev Med , vol.66 , pp. 83-95
    • Ciombor, K.K.1    Wu, C.2    Goldberg, R.M.3
  • 57
    • 84979592925 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT01274624
    • ClinicalTrials.gov Identifier: NCT01274624. Available from: URL: https://clinicaltrials.gov/
  • 58
    • 18044387648 scopus 로고    scopus 로고
    • Raf kinase as a target for anticancer therapeutics
    • PMID: 15827342
    • Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005; 4: 677-685 [PMID: 15827342 DOI: 10.1158/1535-7163.MCT-04-0297]
    • (2005) Mol Cancer Ther , vol.4 , pp. 677-685
    • Sridhar, S.S.1    Hedley, D.2    Siu, L.L.3
  • 61
    • 84862026304 scopus 로고    scopus 로고
    • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    • PMID: 22446022
    • Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475 [PMID: 22446022 DOI: 10.1016/j.ejca.2012.02.057]
    • (2012) Eur J Cancer , vol.48 , pp. 1466-1475
    • Bokemeyer, C.1    Van Cutsem, E.2    Rougier, P.3    Ciardiello, F.4    Heeger, S.5    Schlichting, M.6    Celik, I.7    Köhne, C.H.8
  • 65
    • 79956310674 scopus 로고    scopus 로고
    • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
    • PMID: 21228335
    • Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546 [PMID: 21228335 DOI: 10.1093/annonc/mdq632]
    • (2011) Ann Oncol , vol.22 , pp. 1535-1546
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3    De Braud, F.4    Schuch, G.5    Zubel, A.6    Celik, I.7    Schlichting, M.8    Koralewski, P.9
  • 72
    • 0022789685 scopus 로고
    • Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT)
    • PMID: 3549875
    • Kelway B, Simpson KH, Smith RJ, Halsall PJ. Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT). Int Clin Psychopharmacol 1986; 1: 296-302 [PMID: 3549875 DOI: 10.1158/1078-0432]
    • (1986) Int Clin Psychopharmacol , vol.1 , pp. 296-302
    • Kelway, B.1    Simpson, K.H.2    Smith, R.J.3    Halsall, P.J.4
  • 73
    • 84979540512 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT01750918; NCT01719380
    • ClinicalTrials.gov Identifier: NCT01750918; NCT01719380. Available from: URL: https://clinicaltrials.gov/
  • 76
    • 79957523828 scopus 로고    scopus 로고
    • KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
    • PMID: 21163703
    • De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603 [PMID: 21163703 DOI: 10.1016/S1470-2045(10)70209-6]
    • (2011) Lancet Oncol , vol.12 , pp. 594-603
    • De Roock, W.1    De Vriendt, V.2    Normanno, N.3    Ciardiello, F.4    Tejpar, S.5
  • 78
    • 33344462540 scopus 로고    scopus 로고
    • Mutation of the PIK3CA oncogene in human cancers
    • PMID: 16449998
    • Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 455-459 [PMID: 16449998 DOI: 10.1038/sj.bjc.6602970]
    • (2006) Br J Cancer , vol.94 , pp. 455-459
    • Karakas, B.1    Bachman, K.E.2    Park, B.H.3
  • 81
    • 84860634396 scopus 로고    scopus 로고
    • PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
    • PMID: 22039088
    • Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012; 23: 1518-1525 [PMID: 22039088 DOI: 10.1093/annonc/mdr464]
    • (2012) Ann Oncol , vol.23 , pp. 1518-1525
    • Mao, C.1    Yang, Z.Y.2    Hu, X.F.3    Chen, Q.4    Tang, J.L.5
  • 82
    • 84900569919 scopus 로고    scopus 로고
    • Antiepidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: A meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients
    • PMID: 24701207
    • Huang L, Liu Z, Deng D, Tan A, Liao M, Mo Z, Yang X. Antiepidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci 2014; 10: 1-9 [PMID: 24701207 DOI: 10.5114/aoms.2014.40728]
    • (2014) Arch Med Sci , vol.10 , pp. 1-9
    • Huang, L.1    Liu, Z.2    Deng, D.3    Tan, A.4    Liao, M.5    Mo, Z.6    Yang, X.7
  • 85
    • 4344602002 scopus 로고    scopus 로고
    • The biology and clinical relevance of the PTEN tumor suppressor pathway
    • PMID: 15254063
    • Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963 [PMID: 15254063 DOI: 10.1200/JCO.2004.02.141]
    • (2004) J Clin Oncol , vol.22 , pp. 2954-2963
    • Sansal, I.1    Sellers, W.R.2
  • 89
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • Cancer Genome Atlas Network PMID: 22810696
    • Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
    • (2012) Nature , vol.487 , pp. 330-337
  • 91
    • 84893249799 scopus 로고    scopus 로고
    • PI3K and cancer: Lessons, challenges and opportunities
    • PMID: 24481312
    • Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156 [PMID: 24481312 DOI: 10.1038/nrd4204]
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 140-156
    • Fruman, D.A.1    Rommel, C.2
  • 92
    • 84922092092 scopus 로고    scopus 로고
    • A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
    • PMID: 25335932
    • Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C, Infante JR, Barton J, Burris HA. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs 2015; 33: 187-193 [PMID: 25335932 DOI: 10.1007/s10637-014-0177-3]
    • (2015) Invest New Drugs , vol.33 , pp. 187-193
    • Bendell, J.C.1    Jones, S.F.2    Hart, L.3    Spigel, D.R.4    Lane, C.M.5    Earwood, C.6    Infante, J.R.7    Barton, J.8    Burris, H.A.9
  • 93
    • 84979542650 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT01139138
    • ClinicalTrials.gov Identifier: NCT01139138
  • 94
    • 63349097231 scopus 로고    scopus 로고
    • Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
    • PMID: 19194827
    • Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009; 27: 273-285 [PMID: 19194827 DOI: 10.1080/0735790080231489 3]
    • (2009) Cancer Invest , vol.27 , pp. 273-285
    • Zhang, Y.J.1    Tian, X.Q.2    Sun, D.F.3    Zhao, S.L.4    Xiong, H.5    Fang, J.Y.6
  • 95
    • 84942279909 scopus 로고    scopus 로고
    • Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers
    • PMID: 26404261
    • Temraz S, Mukherji D, Shamseddine A. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci 2015; 16: 22976-22988 [PMID: 26404261 DOI: 10.3390/ijms160922976]
    • (2015) Int J Mol Sci , vol.16 , pp. 22976-22988
    • Temraz, S.1    Mukherji, D.2    Shamseddine, A.3
  • 96
    • 84979508345 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT01363232; NCT01449058
    • ClinicalTrials.gov Identifier: NCT01363232; NCT01449058. Available from: URL: https://clinicaltrials.gov/
  • 98
    • 0042307325 scopus 로고    scopus 로고
    • The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    • PMID: 12853564
    • Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8938 [PMID: 12853564 DOI: 10.1073/pnas.1537685100]
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 8933-8938
    • Holbro, T.1    Beerli, R.R.2    Maurer, F.3    Koziczak, M.4    Barbas, C.F.5    Hynes, N.E.6
  • 105
    • 84979559086 scopus 로고    scopus 로고
    • Presented at AACR Annual Meeting, April 18-21, 2015, Philadelphia, PA
    • Presented at AACR Annual Meeting, April 18-21, 2015, Philadelphia, PA. Available from: URL: http://qfuse.com/client-downloads/AACR 2015-DARECK-poster-15Apr15.pdf
  • 106
    • 84951766343 scopus 로고    scopus 로고
    • Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. Cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC)
    • Price TJ, Newhall J, Peeters M. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33 Suppl 3: abstract 740
    • (2015) J Clin Oncol , vol.33
    • Price, T.J.1    Newhall, J.2    Peeters, M.3
  • 107
    • 76549085643 scopus 로고    scopus 로고
    • Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy
    • PMID: 20068188
    • Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 588-597 [PMID: 20068188 DOI: 10.1158/0008-5472.CAN-09-1417]
    • (2010) Cancer Res , vol.70 , pp. 588-597
    • Pedersen, M.W.1    Jacobsen, H.J.2    Koefoed, K.3    Hey, A.4    Pyke, C.5    Haurum, J.S.6    Kragh, M.7
  • 110
    • 44449151030 scopus 로고    scopus 로고
    • Drug development of MET inhibitors: Targeting oncogene addiction and expedience
    • PMID: 18511928
    • Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516 [PMID: 18511928 DOI: 10.1038/nrd2530]
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 504-516
    • Comoglio, P.M.1    Giordano, S.2    Trusolino, L.3
  • 112
    • 84926361705 scopus 로고    scopus 로고
    • Prognostic value of c-Met in colorectal cancer: A meta-analysis
    • PMID: 25834339
    • Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol 2015; 21: 3706-3710 [PMID: 25834339 DOI: 10.3748/wjg.v21.i12.3706]
    • (2015) World J Gastroenterol , vol.21 , pp. 3706-3710
    • Liu, Y.1    Yu, X.F.2    Zou, J.3    Luo, Z.H.4
  • 116
    • 84979615842 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT02008383
    • ClinicalTrials.gov Identifier: NCT02008383. Available from: URL: https://clinicaltrials.gov/
  • 120
    • 78751480476 scopus 로고    scopus 로고
    • MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy
    • PMID: 21118963
    • Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011; 71: 445-453 [PMID: 21118963 DOI: 10.1158/0008-5472.CAN-10-3058]
    • (2011) Cancer Res , vol.71 , pp. 445-453
    • Yoon, J.1    Koo, K.H.2    Choi, K.Y.3
  • 122
    • 66249116702 scopus 로고    scopus 로고
    • PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
    • PMID: 19401449
    • Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-4293 [PMID: 19401449 DOI: 10.1158/0008-5472. CAN-08-4765]
    • (2009) Cancer Res , vol.69 , pp. 4286-4293
    • Wee, S.1    Jagani, Z.2    Xiang, K.X.3    Loo, A.4    Dorsch, M.5    Yao, Y.M.6    Sellers, W.R.7    Lengauer, C.8    Stegmeier, F.9
  • 123
    • 84904388268 scopus 로고    scopus 로고
    • Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition
    • PMID: 24812410
    • Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 2014; 20: 3775-3786 [PMID: 24812410 DOI: 10.1158/1078-0432. CCR-13-2181]
    • (2014) Clin Cancer Res , vol.20 , pp. 3775-3786
    • Troiani, T.1    Napolitano, S.2    Vitagliano, D.3    Morgillo, F.4    Capasso, A.5    Sforza, V.6    Nappi, A.7    Ciardiello, D.8    Ciardiello, F.9    Martinelli, E.10
  • 126
    • 78651081207 scopus 로고    scopus 로고
    • Safety and efficacy of panitumumab therapy after progression with cetuximab: Experience at two institutions
    • PMID: 21208847
    • Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010; 9: 315-318 [PMID: 21208847 DOI: 10.3816/CCC.2010.n.046]
    • (2010) Clin Colorectal Cancer , vol.9 , pp. 315-318
    • Saif, M.W.1    Kaley, K.2    Chu, E.3    Copur, M.S.4
  • 127
    • 84979615821 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT02296203; NCT02316496
    • ClinicalTrials.gov Identifier: NCT02296203; NCT02316496. Available from: URL: https://clinicaltrials.gov/
  • 132
    • 84979636518 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT02298946; NCT01375842; NCT02335918; NCT01633970; NCT01772004; NCT02227667
    • ClinicalTrials.gov Identifier: NCT02298946; NCT01375842; NCT02335918; NCT01633970; NCT01772004; NCT02227667. Available from: URL: https://clinicaltrials.gov/
  • 134
    • 84979634063 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT01309126; NCT02318901
    • ClinicalTrials.gov Identifier: NCT01309126; NCT02318901. Available from: URL: https://clinicaltrials.gov/


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.